Sermorelin
Compound snapshot
Class
Research peptide
FDA approved
No
Clinical development
Approved
Last reviewed
September 2026
Research areas
Growth hormone axis / Body composition / Recovery
Regulatory status
Investigational (in trials)
Internet attention
Moderate
Registry query
Sermorelin
The first 29 amino acids of natural GHRH — historically an FDA-approved diagnostic and paediatric growth product (Geref), later withdrawn from the US market for commercial reasons.
Reality check — what we actually know
Supported by human evidence
- No adequately powered randomised human trials establish the outcomes this compound is marketed for.
Animal research only
- Preserves the negative-feedback loop, so overshoot is less likely than with exogenous GH
- Historically validated as a test of pituitary GH reserve
- Studied for sleep quality and body-composition change in adult GH deficiency
Mechanistically plausible
- Short-acting GHRH receptor agonist producing a natural-shaped GH pulse that is still regulated by the body's own somatostatin brake.
Common internet claims
- Online discussion frequently presents Sermorelin as a proven treatment rather than a research compound.
Not established
- Human efficacy for the outcomes commonly claimed
- Optimal route, quantity and duration in humans
- Long-term human safety
Evidence distribution
Each band is a live PubMed search for Sermorelin, filtered to that kind of study. Top is the strongest evidence; the base is reasoning, not proof. A band with no records means that kind of study has not been published for this compound yet.
Mechanism and reported findings
Short-acting GHRH receptor agonist producing a natural-shaped GH pulse that is still regulated by the body's own somatostatin brake.
- Preserves the negative-feedback loop, so overshoot is less likely than with exogenous GH
- Historically validated as a test of pituitary GH reserve
- Studied for sleep quality and body-composition change in adult GH deficiency
Strength of the evidence: Real historical regulatory approval and human data, but no current approved product; today's supply is compounded or research-grade.
Safety and known cautions
Compounded supply is unregulated for potency. Same GH-axis cautions.
Evidence at a glance
No single score, on purpose. The line beside each bar shows how much reported outcomes vary between studies.
Development stage
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
- Regulatory review
- ApprovedCurrent